Amazoniac
Member
I believe this is the product in question, sounds a bit suspicious but it's what's claimed:
- US9849148B2 - Magnesium-containing products and uses thereof | Google Patents
"When administered orally, magnesium was shown to be absorbed primarily in the small intestine in the ileum and jejunum, and the degree of absorption has been shown to depend upon the amount of magnesium already present in the diet and the amount of magnesium administered. As indicated by radioactive 28Mg studies, absorption begins approximately 1 hour after oral intake, plateaus after 2-5 hours, and then declines. After 6 hours Mg absorption [of the fractional dose to be uptaken] is about 80% complete."
"Studies have shown that inorganic magnesium salts may have a bioavailability equivalent to organic magnesium salts, depending on the preparation (Firoz and Graber, 2001). It has further been shown that magnesium salts are converted to magnesium chloride in the stomach (Seelig, 1989). Non-absorbed magnesium (not uptaken by cells), due to high oral loads or inefficient absorption, can cause a number of side effects, including diarrhea, heartburn, nausea, and upset stomach."
"It is to be noted that oral administration of acidic magnesium salts, which generate relatively strong acids in the stomach (e.g., magnesium chloride and magnesium sulfate) is limited by the tolerable amount that can be taken, since it can cause non-tolerable acidity in the stomach." ¿
"Several means have been devised to overcome the poor absorption of MgO. Efforts were made to utilize small MgO particles, yet, are hindered by the tendency of the magnesium oxide particles to strongly agglomerate. Resulting agglomerates require a high shear force for re-pulverization at the time of incorporation into absorbable preparations, and thus adversely affect other ingredients in any planned preparations."
"Magnesium oxide, also known as the mineral periclase, can be formed by calcination at high temperatures from magnesium carbonate (Liu et al, 1997), by thermal decomposition of magnesium chloride (Jost et al. 1997), or by dehydration of magnesium hydroxide."
"The present invention [¿], in some embodiments thereof, relates to the field of supplemental products, and more particularly, to magnesium (Mg)-containing products, for use as magnesium supplements to provide enhanced bioavailability of magnesium in humans. In particular, the present invention relates to a composition according to the claims including a hydrate form of magnesium oxide, denoted as MgO·(H2O)n, at a concentration ranging from 10-95% weight percent (wt%), where n is any value from 0.1 to 2. The inventor discovered that a special form of magnesium oxide is useful to overcome not only the problems of agglomeration but also to provide enhanced bioavailability of magnesium."
"In a search for an effective magnesium source that can be efficiently used orally as a magnesium-containing supplement, it was uncovered that magnesium oxide salts, e.g., from the Dead Sea (Israel), exhibit improved pharmacological effects, particularly in terms of cellular uptake (intracellular absorption) and, thus, exhibit a superior performance, as compared to other currently available Mg-containing supplements."
"More particularly, it was uncovered that products containing unique magnesium oxide salts from the Dead Sea exhibit enhanced dissolution and consequently enhanced generation of Mg2+ ions, under acidic conditions. In parallel, it was discovered that oral administration of products containing these specific magnesium oxide salts results in elevated levels of intracellular magnesium [Mg2+]i, which were not observed when other magnesium-containing products were used."
"In the broadest scope of the invention, the magnesium-containing products disclosed herein comprise a hydrate form of magnesium oxide, preferably from the Dead Sea. Without being bound to theory, it was hypothesized by the inventor, with reference to magnesium salts from the Dead Sea, that the extreme climatic conditions of this region have an impact on the formation of such a unique and specific form of Magnesium oxide which exhibits X-ray powder patterns characteristic of a hydrate form of MgO (see, Ball and Taylor, 1961, supra). This hydrate form of magnesium oxide is a fine, slightly gray powder. According to preferred embodiments, this magnesium oxide hydrate is taken, as is, from the Dead Sea and used in an unprocessed form. While such a hydrate compound can be manufactured in synthetic form for use in the pharmaceutical compositions of the present invention, it is much more costly to prepare in this fashion."
"One such exemplary magnesium-containing powder exhibits the following characteristics:"
"Studies have shown that inorganic magnesium salts may have a bioavailability equivalent to organic magnesium salts, depending on the preparation (Firoz and Graber, 2001). It has further been shown that magnesium salts are converted to magnesium chloride in the stomach (Seelig, 1989). Non-absorbed magnesium (not uptaken by cells), due to high oral loads or inefficient absorption, can cause a number of side effects, including diarrhea, heartburn, nausea, and upset stomach."
"It is to be noted that oral administration of acidic magnesium salts, which generate relatively strong acids in the stomach (e.g., magnesium chloride and magnesium sulfate) is limited by the tolerable amount that can be taken, since it can cause non-tolerable acidity in the stomach." ¿
"Several means have been devised to overcome the poor absorption of MgO. Efforts were made to utilize small MgO particles, yet, are hindered by the tendency of the magnesium oxide particles to strongly agglomerate. Resulting agglomerates require a high shear force for re-pulverization at the time of incorporation into absorbable preparations, and thus adversely affect other ingredients in any planned preparations."
"Magnesium oxide, also known as the mineral periclase, can be formed by calcination at high temperatures from magnesium carbonate (Liu et al, 1997), by thermal decomposition of magnesium chloride (Jost et al. 1997), or by dehydration of magnesium hydroxide."
"The present invention [¿], in some embodiments thereof, relates to the field of supplemental products, and more particularly, to magnesium (Mg)-containing products, for use as magnesium supplements to provide enhanced bioavailability of magnesium in humans. In particular, the present invention relates to a composition according to the claims including a hydrate form of magnesium oxide, denoted as MgO·(H2O)n, at a concentration ranging from 10-95% weight percent (wt%), where n is any value from 0.1 to 2. The inventor discovered that a special form of magnesium oxide is useful to overcome not only the problems of agglomeration but also to provide enhanced bioavailability of magnesium."
"In a search for an effective magnesium source that can be efficiently used orally as a magnesium-containing supplement, it was uncovered that magnesium oxide salts, e.g., from the Dead Sea (Israel), exhibit improved pharmacological effects, particularly in terms of cellular uptake (intracellular absorption) and, thus, exhibit a superior performance, as compared to other currently available Mg-containing supplements."
"More particularly, it was uncovered that products containing unique magnesium oxide salts from the Dead Sea exhibit enhanced dissolution and consequently enhanced generation of Mg2+ ions, under acidic conditions. In parallel, it was discovered that oral administration of products containing these specific magnesium oxide salts results in elevated levels of intracellular magnesium [Mg2+]i, which were not observed when other magnesium-containing products were used."
"In the broadest scope of the invention, the magnesium-containing products disclosed herein comprise a hydrate form of magnesium oxide, preferably from the Dead Sea. Without being bound to theory, it was hypothesized by the inventor, with reference to magnesium salts from the Dead Sea, that the extreme climatic conditions of this region have an impact on the formation of such a unique and specific form of Magnesium oxide which exhibits X-ray powder patterns characteristic of a hydrate form of MgO (see, Ball and Taylor, 1961, supra). This hydrate form of magnesium oxide is a fine, slightly gray powder. According to preferred embodiments, this magnesium oxide hydrate is taken, as is, from the Dead Sea and used in an unprocessed form. While such a hydrate compound can be manufactured in synthetic form for use in the pharmaceutical compositions of the present invention, it is much more costly to prepare in this fashion."
"One such exemplary magnesium-containing powder exhibits the following characteristics:"
- "Purity of about 96.4%;"
- "Residual amount of non-Mg impurities of about 0.7%;"
- "As shown herein, the particles vary in size but exhibit a d70 (average particle size of 70% of the granules) of 30-60 mesh."
